Therapeutic Nucleic Acids: Advanced Solutions for Downstream Processing & Analysis

Learn how to select and optimize strategies to effectively address the different impurities of therapeutic nucleic acids. Join us for a deep dive into how chromatography is evolving to meet the demands of next-generation oligonucleotide therapeutics.

Register Free: https://www.biopharminternational.com/bp_w/therapeuticnucleic

Event Overview:

The rapid growth of oligonucleotide-based therapeutics has introduced new challenges in purification and analytical characterization, driven by their structural complexity and diverse impurity profiles. This presentation explores the latest advancements in chromatographic techniques developed specifically for therapeutic oligonucleotides. It examines how to select and optimize strategies to address different classes of impurities, ranging from shortmers and longmers to process-related contaminants. Through case studies that illustrate practical applications, the presentation highlights innovative solutions designed to improve efficiency and product quality. It offers a deep dive into how chromatography is evolving to meet the demands of next-generation oligonucleotide therapeutics.

Key Learning Objectives:

• Understand the challenges and complexity of therapeutic oligonucleotides
• Learn to evaluate and optimize chromatographic strategies
• Apply lessons learned from industry case studies

Who Should Attend:

• Process development scientists focused on purification and scale-up of therapeutic oligonucleotides
• Analytical scientists and chemists working on oligonucleotide characterization and quality control
• Chromatography specialists and method development scientists seeking advanced strategies for impurity resolution
• Regulatory and quality assurance professionals interested in analytical robustness and compliance for oligonucleotide therapeutics
• Biopharmaceutical R&D professionals involved in next-generation oligonucleotide drug development

Speaker:

Patrick Endres, MSc
Head of Global Product Management
Tosoh Bioscience

Patrick Endres holds an MSc degree in bioengineering from the Karlsruhe Institute of Technology and joined Tosoh Bioscience in 2014. After various technical positions within Tosoh, he transitioned to product management in 2022. He currently leads the global product management team, responsible for Tosoh Bioscience’s process resins, prepacked columns and multicolumn chromatography systems.

Register Free: https://www.biopharminternational.com/bp_w/therapeuticnucleic